Skip to main content

Featured

Gingerbread Cookies

These cookies are warmly spiced, with crisp edges and soft centers—perfect for holiday decorating and eating. Ingredients 3 cups all-purpose flour ¾ teaspoon baking soda ¼ teaspoon salt 1 tablespoon ground ginger 1 tablespoon ground cinnamon ½ teaspoon ground cloves ½ teaspoon ground nutmeg 8 tablespoons (1 stick) unsalted butter, softened ¾ cup packed dark brown sugar ¾ cup unsulfured molasses 1 large egg Instructions Mix dry ingredients : In a medium bowl, whisk flour, baking soda, salt, and spices. Cream butter & sugar : In a large bowl, beat butter and brown sugar until fluffy. Add molasses and egg. Combine : Gradually add dry mixture until dough forms. Chill dough : Divide into two disks, wrap in plastic, and refrigerate for at least 1 hour. Roll & cut : Roll dough to ¼-inch thickness. Cut into shapes with cookie cutters. Bake : Place on parchment-lined sheets and bake at 350°F for 8–10 minutes, until edges are set. Cool & decorate : Let cool com...
Post a Comment
Read more

article

Labels

Alzheimer’s Drug Donanemab Receives FDA Advisers’ Endorsement for Slowing Disease Progression

 

A significant milestone has been reached in the fight against Alzheimer’s disease. Eli Lilly’s closely watched Alzheimer’s drug, donanemab, has won the unanimous backing of federal health advisers. The drug is specifically intended for people with mild dementia caused by this brain-robbing disease.

The decision by the Food and Drug Administration (FDA) advisers comes after careful consideration of the drug’s benefits and risks. Donanemab has demonstrated the ability to modestly slow cognitive decline and memory problems associated with Alzheimer’s. Although it’s not a cure, this endorsement represents a promising step forward in managing the disease.

Here are the key points:

  1. Effectiveness: Donanemab has shown effectiveness in slowing cognitive decline. Patients who received monthly intravenous infusions of the drug declined about 35% more slowly than those who received a placebo.
  2. Risk Assessment: The FDA panel weighed the risks, including side effects like brain swelling and bleeding, which will need monitoring. Despite these risks, the panel concluded that the drug’s benefits outweighed them.
  3. Tau Protein Screening: Unlike previous concerns about tau protein screening, most panelists believed there was enough evidence to prescribe the drug broadly without requiring such screening.
  4. FDA Decision: The FDA will make the final decision on approval later this year. If approved, donanemab would become only the second Alzheimer’s drug in the U.S. shown to convincingly slow cognitive decline.

This endorsement brings hope to individuals and families affected by Alzheimer’s, and we eagerly await the FDA’s final decision. Stay tuned for further updates on this groundbreaking development! 

Labels:

Comments

Post a Comment